International Journal of Frontiers in Medicine, 2024, 6(5); doi: 10.25236/IJFM.2024.060508.
Jin Chen1, Pinzhi Dong1, Yuan Ke1, Langlang Zhang1, Yuhan Yang1, Yingnong Wu1, Yudi Jin1, Jihong Feng2, Junmin Luo1
1Department of Immunology, Zunyi Medical University, Zunyi, China
2Department of Oncology, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui People's Hospital, Lishui, China
GAB2 is closely associated with the development of a variety of tumors. However, the detailed function and role of GAB2 in pan-cancer are largely unknown and require further in-depth investigation. Consequently, this study aims to investigate the biological functions of GAB2, and its potential to predict prognosis in pan-cancer. We applied multiple public databases such as TCGA, TIMER, GTEx, and CCLE to explore GAB2 expression in tumors. Univariate Cox regression and Kaplan-Meier survival analysis were used to detect the effects of GAB2 on OS, DSS, DFI, and PFI in these patients. It turns out that GAB2 expression was elevated in most tumor tissues compared to normal tissues, and was positively or negatively correlated with the prognosis of different tumors. Generally, comprehensive pan-cancer analysis identified GAB2 as a prognostic biomarker.
GAB2, prognosis, pan-cancer, the Cancer Genome Atlas
Jin Chen, Pinzhi Dong, Yuan Ke, Langlang Zhang, Yuhan Yang, Yingnong Wu, Yudi Jin, Jihong Feng, Junmin Luo. Comprehensive pan-cancer analysis identified GAB2 as a prognostic biomarker. International Journal of Frontiers in Medicine (2024), Vol. 6, Issue 5: 48-54. https://doi.org/10.25236/IJFM.2024.060508.
[1] E Dolgin. Cancer's new normal[J]. Nat Cancer, 2021, 2(12): 1248-1250.
[2] A Mullard. Addressing cancer's grand challenges[J]. Nat Rev Drug Discov, 2020, 19(12): 825-826.
[3] N Wang, Zhu L, Wang L, et al. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers[J]. Comput Struct Biotechnol J, 2022, 203106-3119.
[4] S-J Adams, Aydin I-T, Celebi J-T. GAB2--a scaffolding protein in cancer[J]. Mol Cancer Res, 2012, 10(10): 1265-1270.
[5] R Gong, Li H, Liu Y, et al. Gab2 promotes acute myeloid leukemia growth and migration through the SHP2-Erk-CREB signaling pathway[J]. J Leukoc Biol, 2022, 112(4): 669-677.
[6] V Kondreddy, Magisetty J, Keshava S, et al. Gab2 (Grb2-Associated Binder2) Plays a Crucial Role in Inflammatory Signaling and Endothelial Dysfunction[J]. Arterioscler Thromb Vasc Biol, 2021, 41(6): 1987-2005.
[7] W Shioyama, Nakaoka Y, Higuchi K, et al. Docking protein Gab1 is an essential component of postnatal angiogenesis after ischemia via HGF/c-met signaling[J]. Circ Res, 2011, 108(6): 664-675.
[8] I Wolf, Jenkins B-J, Liu Y, et al. Gab3, a new DOS/Gab family member, facilitates macrophage differentiation [J]. Mol Cell Biol, 2002, 22(1): 231-244.
[9] G Sarmay, Angyal A, Kertesz A, et al. The multiple function of Grb2 associated binder (Gab) adaptor/scaffolding protein in immune cell signaling[J]. Immunol Lett, 2006, 104(1-2): 76-82.
[10] C Niu, Li M, Chen Y, et al. LncRNA NCAL1 potentiates natural killer cell cytotoxicity through the Gab2-PI3K-AKT pathway[J]. Front Immunol, 2022, 13970195.
[11] C Spohr, Poggio T, Andrieux G, et al. Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo[J]. Leukemia, 2022, 36(4): 970-982.
[12] C Ding, Luo J, Li L, et al. Gab2 facilitates epithelial-to-mesenchymal transition via the MEK/ERK/MMP signaling in colorectal cancer[J]. J Exp Clin Cancer Res, 2016, 355.
[13] Y Yang, Wu J, Demir A, et al. GAB2 induces tumor angiogenesis in NRAS-driven melanoma[J]. Oncogene, 2013, 32(31): 3627-3637.
[14] J Cheng, Zhong Y, Chen S, et al. Gab2 mediates hepatocellular carcinogenesis by integrating multiple signaling pathways [J]. FASEB J, 2017, 31(12): 5530-5542.
[15] Gao X, Long R, Feng J., et al. Gab2 promotes the growth of colorectal cancer by regulating the M2 polarization of tumor‑associated macrophages [J]. Int J Mol Med. 2024 Jan;53(1):3.